No Data
No Data
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Raises Target Price to $5
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Design Therapeutics GAAP EPS of -$0.24
Design Therapeutics | 10-K: FY2024 Annual Report